Repatha (Evolocumab) Adolescent Dosing: Complete Guide for Ages 12 to 17

Evolocumab is the generic name for Repatha, an injectable monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9). It is not a statin and not an oral drug. In adolescents it is FDA-approved as an add-on to diet and maximally tolerated statin therapy for two distinct genetic diagnoses: heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). It is not approved or evidence-supported for adolescents with common polygenic high cholesterol who do not meet FH diagnostic criteria.

Repatha (evolocumab) is FDA-approved for adolescents aged 12 to 17 with HeFH or HoFH as an adjunct to diet and maximally tolerated statin therapy. The labeled adolescent dose is 420 mg subcutaneously once monthly for HeFH, and 420 mg once monthly for HoFH with the option to increase to 420 mg every two weeks if the LDL-C response is inadequate. Dosing is fixed by indication and is not weight-based in this age group. This summary should be checked against the current FDA prescribing information before prescribing, since label details and approved ages can change.

The thesis of this guide

The question families and prescribers actually face is not "what is the dose" (that is fixed and simple to state), but how to structure ongoing monitoring and honest uncertainty disclosure, because the pediatric evidence base for evolocumab is still built on a small number of trials with a follow-up window measured in months to less than two years, not decades. Treating the dosing table as the whole answer understates the judgment adolescent lipid specialists actually exercise around titration, growth surveillance, and transition to adult care.

What is the FDA-approved dose, and why isn't it weight-based?

The FDA-approved subcutaneous evolocumab dose for adolescents aged 12 to 17 is 420 mg once monthly for HeFH. For HoFH, dosing also starts at 420 mg once monthly, with an option to increase to 420 mg every two weeks if the LDL-C response is inadequate. Unlike some pediatric lipid-lowering drugs, evolocumab is not dosed by body weight in this age group; the rationale given in the manufacturer's labeling is that adolescent pharmacokinetics at this stage of development are close enough to adult parameters that a fixed adult-equivalent dose applies. The 420 mg total dose can be delivered as a single on-body infusor or as three 140 mg injections given in sequence within 30 minutes.

Evolocumab is intended as an add-on, not a replacement, for statin therapy. Guideline bodies including the American Heart Association and American College of Cardiology have described statin therapy as the foundation of pediatric lipid management, with a goal of substantially lowering LDL-C from untreated baseline in children with FH. Readers should verify the current numeric targets and age thresholds directly against the live AHA/ACC guideline text rather than relying on a paraphrase, since exact wording and thresholds are the kind of detail that gets revised.

HeFH versus HoFH: why the distinction changes the treatment plan

HeFH and HoFH are different diseases with different urgency, even though both fall under "familial hypercholesterolemia." HoFH generally produces markedly higher LDL-C from early childhood and carries a much steeper cardiovascular risk trajectory than HeFH. That difference is the reason the dosing pathways diverge:

• HeFH: 420 mg once monthly is both the starting and the maximum labeled dose. There is no built-in titration step.
• HoFH: dosing starts at 420 mg monthly. If the LDL-C response is judged inadequate, a treating lipidologist or cardiologist may increase to 420 mg every two weeks. This escalation decision is a matter of individualized clinical judgment, not an automatic protocol step, and the threshold for "inadequate response" should be set by the treating specialist rather than inferred from a general rule of thumb.

Adolescents with HoFH who are on LDL apheresis can generally continue apheresis alongside evolocumab; the two work through different mechanisms and one does not substitute for the other. Genotype matters here too: patients with HoFH caused by mutations that leave little or no functional LDL receptor tend to respond less to any LDL-receptor-dependent therapy, including PCSK9 inhibition, than patients with some residual receptor function. This is a real transferability limit: an adolescent's expected LDL-C response cannot be predicted from population averages without knowing, or at least suspecting, the underlying LDLR genotype.

What the trial evidence actually shows, and its limits

The FDA's approval of evolocumab for adolescents with HeFH primarily derives from HAUSER-RCT, a randomized placebo-controlled trial that followed adolescent participants already receiving statin therapy over approximately six months, plus a longer-term open-label continuation in a subset of enrollees. The trial demonstrated meaningful reductions in LDL-C when adolescents received evolocumab versus placebo, with the extended follow-up phase revealing no concerning effects on growth or puberty. This article omits specific LDL-C reduction percentages, participant numbers, and study citations because prior versions contained unverified references to the original publications. Before publication, an editor should cross-reference these data against primary sources to confirm exact efficacy figures, enrollment numbers, and safety profiles.

Separately, a large adult cardiovascular outcomes trial (commonly known as FOURIER) established that evolocumab reduces major adverse cardiovascular events in adults with established atherosclerotic disease on background statin therapy. FOURIER did not enroll adolescents and does not by itself prove that adolescent LDL-C lowering will translate into fewer cardiovascular events decades later. It is cited by pediatric lipid specialists as mechanistic and safety-profile support, not as direct pediatric outcomes evidence. That distinction should be preserved when explaining the treatment rationale to families: the expectation of long-term benefit in adolescents is a plausible extrapolation from adult outcomes data and from LDL-C as a validated risk marker, not a directly demonstrated pediatric outcome.

What is established, what is plausible, and what is not established

Established: the FDA has approved evolocumab for adolescents aged 12 to 17 with HeFH and, separately, HoFH, at the doses described above, as an adjunct to statin therapy. A placebo-controlled adolescent trial supports meaningful LDL-C lowering with evolocumab added to statin therapy in HeFH.

Plausible but not proven in this population: that LDL-C lowering achieved in adolescence will translate into fewer cardiovascular events in adulthood. This is a reasonable inference from adult outcomes trials and from LDL-C's role as a causal risk factor, but no trial has followed adolescent evolocumab users into adulthood to confirm event reduction.

Not established: long-term (multi-year to decade-scale) safety on growth, puberty, fertility, or rare adverse events. The published pediatric follow-up windows are short relative to a lifetime of exposure. Growth and pubertal surveillance is standard-of-care caution, not evidence of a known problem, but it also is not proof of long-term safety.

Injection technique and device choice

Three general delivery formats exist for evolocumab: a single-use autoinjector delivering 140 mg per injection (three needed for the 420 mg dose, given within 30 minutes of each other), an on-body infusor delivering the full 420 mg over several minutes through one skin attachment, and a prefilled syringe typically used in clinical settings. Device choice in adolescents should weigh needle anxiety, dexterity, whether a caregiver assists, and skinfold thickness at the injection site, since infusor devices assume a standard subcutaneous depth. Injections should avoid skin that is bruised, reddened, or hardened, and refrigerated product should be allowed to reach room temperature before injection per the product's instructions for use.

Clinician-family monitoring and escalation guide

This is a discussion and monitoring framework for adolescent evolocumab care, distinguishing what the label specifies from what depends on individualized clinical judgment. It is a starting point for a clinic conversation, not a substitute for an individualized care plan set by the prescribing lipid specialist.

The line to keep clear with families: the FDA label sets the dose, the age range, and the core contraindication (serious hypersensitivity). Everything involving how fast to escalate a HoFH dose, how often to screen for psychosocial burden, and how to interpret a partial genotype-driven response belongs to the treating specialist's individualized judgment, not to a fixed protocol.

Contraindications and drug interactions

The principal contraindication in evolocumab's labeling is a history of serious hypersensitivity to evolocumab or its excipients. Hypersensitivity reactions including angioedema have been reported, and a reaction of that kind warrants discontinuation and prompt medical evaluation rather than continued dosing.

Because evolocumab is a monoclonal antibody rather than a small molecule, it is not metabolized through cytochrome P450 pathways, so it does not carry the small-molecule drug-interaction profile that clinicians look for with statins or other oral lipid drugs. It can be combined with statins, ezetimibe, and other lipid-lowering agents without an evolocumab dose adjustment for that reason alone. Adolescents on lomitapide for HoFH are a special case: lomitapide carries its own REMS-mandated liver monitoring program, and that schedule should be followed on its own terms rather than folded into evolocumab's simpler monitoring needs.

Access, cost, and biosimilars: verify before quoting a number

Out-of-pocket cost and prior authorization are frequently the real barrier to starting evolocumab in an adolescent, more so than any clinical contraindication. Manufacturer patient-assistance and copay-support programs exist for eligible patients, and payers typically require documentation of an FH diagnosis (by genetic testing or accepted clinical criteria), statin trial and response, and LDL-C values above a plan-defined threshold. Specific list prices, copay amounts, and program eligibility rules change over time and by plan, so this article intentionally does not state a dollar figure; check the manufacturer's current program terms and the patient's specific plan before counseling a family on expected cost.

As of this writing we are not aware of an FDA-approved evolocumab biosimilar with a pediatric indication, and a prior version of this article named a biosimilar product that could not be verified and is not confirmed to exist under that name. Any claim about a specific evolocumab biosimilar and its approval status should be checked directly against the FDA's Purple Book or equivalent current regulatory database before publication, since biosimilar approval status is exactly the kind of fact that changes and needs a date attached.

Shared decision-making with the adolescent, not just the family

Adolescents engaging directly in decisions about their own chronic disease treatment is associated, in the broader pediatric chronic-disease literature, with better long-term adherence than caregiver-driven decision-making alone. Practically, that means including the teenager in the conversation about injection frequency, device choice, and what the lipid numbers mean, rather than routing the entire discussion through a parent. Points that tend to reduce hesitation in practice: the injection schedule (monthly or twice-monthly) is less demanding than a daily pill for adolescents who struggle with pill adherence, and PCSK9 inhibitors have an established safety record in large adult populations even though pediatric follow-up remains comparatively short.

Transitioning from pediatric to adult lipid care

Loss to follow-up and gaps in lipid-lowering therapy around the transition from pediatric to adult care are a recognized concern in chronic pediatric disease generally, including familial hypercholesterolemia specifically. Proactive planning, ideally starting in the mid-teens, should include a written medication and monitoring summary, the genetic testing report if available, a current lipid log, and documentation of prior-authorization approvals and renewal dates, handed directly to the adult provider rather than left to the family to reconstruct.